HOWARU® Protect Kids
Helps keep children healthy during the cold and flu season
Based on a study published in Pediatrics*, results showed that HOWARU® Protect Kids supported respiratory health with symptom duration shortened from 6.5 to 3.5 days; a strong reduction in antibiotic use and a reduced number of sick days.
HOWARU® Protect Adult
Helps maintain a healthy respiratory function
HOWARU® Protect Adult - Based on a study recently published in Clinical Nutrition*, data demonstrated a 27 percent reduction of risk of upper respiratory tract illness coupled with the delayed onset of respiratory tract illness versus the placebo.
Kordel's Protect Probiotic Powder contains 2 strains of beneficial bacteria, L. acidophillus NCFM, and B. Lactis Bi07.
In one double-blind, placebo-controlled study, 326 eligible children from 3 to 5 years of age were randomised to receive placebo, Lactobacillus acidophilus NCFM®, or Lactobacillus acidophilus NCFM® in combination with Bifidobacterium lactis Bi-07. The children were given the supplement twice each day for a period of 6 months.
The results indicated that, in comparison to the placebo group, both single and combination probiotics reduced incidences of fever by 53.0% and 72.7%, incidences of coughing by 41.4% and 62.1% and rhinorrhoea (runny nose) incidence by 28.2% and 58.8% respectively Fever, coughing, and rhinorrhoea duration was decreased significantly, relative to placebo, by 32% using the single strain and 48% in the group given the strain combination, compared to the placebo group. The need for antibiotics was also reduced, relative to placebo, as was absence from school due to illness, compared with subjects receiving placebo treatment (Leyer G.J., et al. 2009)
In another recent double-blind, randomised, placebo-controlled Australian study, 465 participants who exercised regularly were investigated to see if probiotics would help to support their immune function, as significant exercise can place a burden on the immune system and lead to increased incidence of coughs and colds. The subjects were split into three groups: the subjects in the first group took a supplement containing only Bifidobacterium lactis Bi-07, those in the second group took a combination of L. acidophilus NCFM® & B. lactis Bi-07, and those in the third group were given a placebo.
Over the 5 months of the trial it was found that the first group had a 27% decreased risk of contracting an upper respiratory infection. Those in the second group also had a decrease in their risk of infection, but it was not as significant as that seen in the first group, indicating that it was the Bifidobacterium lactis Bi-07 which offered the greatest potential benefit for immune support; however, both probiotic groups experienced improved immunity compared to the placebo group (West et al., 2014)
Bifidobacteria lactis Bi-07
A double-blind, randomised and controlled trial conducted by Lehtinen et al. (2014) looked at daily supplementation with Bifidobacterium lactis Bi-07 on 37 elderly subjects. The authors found beneficial effects on the immune responses of the participants, noted as an increase in phagocytic activity of both monocytes and granulocytes, one of the immunological mechanisms by which the body helps prevent itself from infections and illness.